
Novartis licenses Genentech's AMD candidate Lucentis
Executive Summary
Novartis Ophthalmics AG licensed exclusive worldwide rights outside of N. America to Genentech's Lucentis (ranibizumab), a drug candidate in US Phase III trials for treating the wet form of age-related macular degeneration (AMD).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com